What question did this study set out to answer?

Evaluate the effectiveness of venetolax plus azacitidine as maintenance therapy after allo-HSCT in AML patients.

December 8, 2025Blood

Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia

View Full Paper

Ask AI

Bookmark

Authors

XXXiaoxuan XuNorthwestern Polytechnical University

Discussion

Member takes

Implication

Retrospective analysis demonstrates that venetolax plus azacitidine improves outcomes in intermediate/high-risk AML post-allogeneic transplantation, indicating effective maintenance therapy.

Key Points

Evaluate the effectiveness of venetolax plus azacitidine as maintenance therapy after allo-HSCT in AML patients.
Retrospective evaluation of 23 patients receiving venetolax plus azacitidine compared to 59 controls without anti-AML therapy.
All patients in the VEN+AZA group received venetolax (200mg/d) and azacitidine (100mg/d) from 3 months after transplantation.
Cumulative incidence of relapse and survival outcomes were analyzed using competing-risk methods and Kaplan-Meier method.
Cumulative incidence of relapse was significantly lower in the VEN+AZA group (8.7%) compared to control (37.3%).
Overall survival at three years was better in the VEN+AZA group (94.1%) than control (61.3%).
Nonrelapse mortality at three years was also superior in the VEN+AZA group (82.4%) compared to control (46.5%).

Cite This Study

Xiaoxuan Xu (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d37c https://doi.org/10.1182/blood-2025-6995

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis demonstrates that venetolax plus azacitidine improves outcomes in intermediate/high-risk AML post-allogeneic transplantation, indicating effective maintenance therapy.

Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Venetolax plus azacitidine is effective maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with intermediate/high-risk Acute Myeloid Leukemia

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider